Social Media, Web 2.0, and the Promotion of FDA-Regulated Medical Products (Recorded Webinar)
Across industries, the use of social media tools and Web 2.0 collaborative technologies has risen to play a prominent role in the marketing of products and services. For those companies promoting prescription drugs, biologics, and medical devices regulated by the United States Food and Drug Administration (FDA), the urge to enter the social media/Web 2.0 marketing fray has been tempered by uncertainties. Click here to view the recorded webinar presentation.
In a step towards providing guidance, the FDA has scheduled public hearings November 12 and 13 to discuss:
- For what online communications are companies accountable (including third-party venues)?
- How can companies fulfill regulatory requirements when the social media/Web 2.0 tools have space limitations and often allow for real-time communications?
- What parameters should apply to the posting of corrective information on Web sites controlled by third-parties?
- When is the use of links appropriate?
- What post-market adverse event monitoring/reporting is expected for social media/Web 2.0 tools?
On November 18, 2009, Nixon Peabody presented an audio seminar addressing these and other social media/Web 2.0 issues for FDA-regulated companies.
The Nixon Peabody audio seminar includes highlights from the FDA hearings, a look at FDA enforcement in this area, and how the use of these technology tools requires integration with corporate records and information management practices.
- Jonathan Redgrave, Partner, Nixon Peabody LLP, Leader of Nixon Peabody’s Information Law Advisors team
- Seth Mailhot, Counsel, Nixon Peabody LLP, Leader of Nixon Peabody’s FDA Regulatory Practice team
- Paulette Morgan, Counsel, Nixon Peabody LLP, formerly Senior Corporate Counsel, Pfizer, Inc.
Click here to view the recorded webinar presentation.
The foregoing has been prepared for the general information of clients and friends of the firm. It is not meant to provide legal advice with respect to any specific matter and should not be acted upon without professional counsel. If you have any questions or require any further information regarding these or other related matters, please contact your regular Nixon Peabody LLP representative. This material may be considered advertising under certain rules of professional conduct.